These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 19576325)
21. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987 [TBL] [Abstract][Full Text] [Related]
22. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Niesor EJ Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074 [TBL] [Abstract][Full Text] [Related]
23. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Schaefer EJ; Asztalos BF Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892 [TBL] [Abstract][Full Text] [Related]
24. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. Derks M; Anzures-Cabrera J; Turnbull L; Phelan M Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361 [TBL] [Abstract][Full Text] [Related]
25. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Barter P; Rye KA Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767 [TBL] [Abstract][Full Text] [Related]
26. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Barter P Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939 [TBL] [Abstract][Full Text] [Related]
28. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Stroes ES; Kastelein JJ; Bénardeau A; Kuhlmann O; Blum D; Campos LA; Clerc RG; Niesor EJ Br J Pharmacol; 2009 Dec; 158(7):1763-70. PubMed ID: 19917065 [TBL] [Abstract][Full Text] [Related]
29. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594 [TBL] [Abstract][Full Text] [Related]
30. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Miyares MA Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945 [TBL] [Abstract][Full Text] [Related]
31. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191 [TBL] [Abstract][Full Text] [Related]
32. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Hermann F; Enseleit F; Spieker LE; Périat D; Sudano I; Hermann M; Corti R; Noll G; Ruschitzka F; Lüscher TF Thromb Res; 2009; 123(3):460-5. PubMed ID: 18789492 [TBL] [Abstract][Full Text] [Related]
33. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Goldberg AS; Hegele RA Drug Des Devel Ther; 2012; 6():251-9. PubMed ID: 23055695 [TBL] [Abstract][Full Text] [Related]
34. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility. Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613 [TBL] [Abstract][Full Text] [Related]
35. The role of CETP inhibition in dyslipidemia. El Harchaoui K; van der Steeg WA; Stroes ES; Kastelein JJ Curr Atheroscler Rep; 2007 Aug; 9(2):125-33. PubMed ID: 17877921 [TBL] [Abstract][Full Text] [Related]
36. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P; Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408 [TBL] [Abstract][Full Text] [Related]
37. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Schaefer EJ; Asztalos BF Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849 [TBL] [Abstract][Full Text] [Related]
38. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Strony J; Hoffman R; Hanson M; Veltri E Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588 [TBL] [Abstract][Full Text] [Related]
39. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879 [TBL] [Abstract][Full Text] [Related]
40. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders]. Rensen PC; Jukema JW Ned Tijdschr Geneeskd; 2008 May; 152(19):1088-90. PubMed ID: 18552062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]